Skip to main content
メニュー
Revvity logo
Contact us
JP
Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong (China) *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States
Breadcrumb
...
  • ホーム
  • Services
  • 臨床サービス
    • Preclinicalサービス
    • Revvity Omics Services
    • 臨床サービス
    • Customization Services
    • ライセンシング
    • Viral Vector Engineering and Manufacture
    • Instrument Service & Maintenance
    • Customer Training
    • OEM ソリューション
  • Cellular and Humoral Immunoassays
    • ViaCord Cord Blood & Cord Tissue Banking
    • Revvity Omics Clinical Services
    • Revvity Omics Pharma Services
    • Cellular and Humoral Immunoassays
    • Tuberculosis Testing Services

Cellular and Humoral Immunoassays

Your trusted immunology experts

Certimmune, from Revvity, offers customized immunology services to companies in the vaccine and immunotherapy markets for their clinical trials, leveraging 20 years of immunology expertise to offer a consultative approach from concept to assay validation. Our global network of labs and simplified logistics allows you to expand your testing capabilities.

Our services

  • Specialized immunology assays

    We have extensive expertise in using Four Colour FluoroSpot, and Flow Cytometry in evaluating the adaptive immune system, including T cells, B cells, dendritic cells, and antibodies.

  • Simplified logistics

    We can process fresh blood up to 32 hours post-draw using T cell stabilization technology. This allows for easier patient recruitment across larger distances.

Request more information
Cellular and Humoral Immunoassays
UK vaccine task force

Sole collaboration to UK Vaccine Task Force

The Certimmune ELISPOT was selected as the sole collaborator to the UK Vaccine Task Force (VTF) to assess T cell responses to vaccines, vaccine dosing strategies and prime-boost regimes.

The Certimmune ELISPOT was selected as the sole collaborator to the UK Vaccine Task Force (VTF) to assess T cell responses to vaccines, vaccine dosing strategies and prime-boost regimes.

Clinical trial samples

26,000 ELISPOT and flow cytometry clinical trial samples

We completed ELISPOT and flow cytometry work on over 26,000 clinical trial samples in 2021.

We completed ELISPOT and flow cytometry work on over 26,000 clinical trial samples in 2021.

Global partnerships

Global collaborations

We have collaborated with many companies, research institutes and governmental bodies in their clinical research.

We have collaborated with many companies, research institutes and governmental bodies in their clinical research.

Global scalability for clinical trial growth

We have an established global network of trusted laboratories to provide testing services for our Certimmune customers. This is enhanced by use of T cell stabilization technology, which allows sample collection across greater distances.

We have an established global network of trusted laboratories to provide testing services for our Certimmune customers. This is enhanced by use of T cell stabilization technology, which allows sample collection across greater distances.

High standards to support regulatory submission

Guided by our Quality Assurance, Clinical Affairs, and Regulatory teams, our products and services adhere to GCP as standard in our labs.

Guided by our Quality Assurance, Clinical Affairs, and Regulatory teams, our products and services adhere to GCP as standard in our labs.

Our global reach

Our global reach

Featured resources

img-1-black

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines

Our study for the UK Vaccine Task Force.

Learn more
img-2-yellow

Safety and immunogenicity of seven COVID-19 vaccines as a third dose

A safety and immunogenicity study of COVID-19 boosters.

Learn more
img-3-yellow

Safety and immunogenicity of heterologous versus homologous prime-boost schedules

A partner study with Oxford University.

Learn more
img-4-black

Shortened Title: Immunogenicity of concomitant SARS-CoV-2 and influenza vaccination

A partner study with the University of Leicester.

Learn more
全てを表示 View less

Questions?
We’re here to help.

Contact us

For research use only. Not for use in diagnostic procedures.

Revvity Logo

©2025 Revvity - All rights reserved

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.